Table 3 Studies on passive immunization in SARS with neutralizing monoclonal antibodies
Type of antibody and method of generation | Antibody target | Animal, route and dose of passive immunization and virus challenge | Response | Reference (ref. no.) |
|---|---|---|---|---|
Human monoclonal antibody (IgG1). Epstein-Barr virus immortalization of memory B cell repertoire from SARS patients augmented by CpG2006. | Spike protein | BALB/c mice. Monoclonal antibody administered intraperitoneally 2 days prior to intranasal challenge with 104 TCID50 SARS-CoV. | 6-log10 decrease in viral titer in lungs (less decrease in nasal swabs). | Traggiai, E. Nat. Med. 2004 (138) |
Human monoclonal antibody (IgG1). Screen naive antibody phage display library IgG1. | Spike protein | Ferret. 10 mg/kg of monoclonal antibody administered 24 hours before intratracheal challenge with 104 TCID50 of virus. | 3.3-log10 decrease in viral titer in lung; decreased shedding from throat Protects from lung pathology. | ter Meulen, J. Lancet 2004 (137) |